{
  "_originalData": {
    "identity": {
      "bacteriumName": "Salmonella sp.",
      "aliases": [
        "Salmonella enterica serovars",
        "Salmonella Typhi",
        "Salmonella Paratyphi",
        "Salmonella Choleraesuis",
        "Salmonella Typhimurium"
      ],
      "lastUpdated": "2023-11-14",
      "clsiCategory": "Salmonella and Shigella spp.",
      "classification": {
        "gramStain": "Gram-negative",
        "morphology": "Bacillus",
        "respiration": "Facultative anaerobe",
        "notes": []
      },
      "strainDetails": [
        {
          "type": "Serovar Group",
          "value": "Typhoidal Salmonella",
          "notes": "Includes S. Typhi and S. Paratyphi, causes enteric fever."
        },
        {
          "type": "Serovar Group",
          "value": "Non-typhoidal Salmonella (NTS)",
          "notes": "Includes serovars like Typhimurium and Enteritidis, typically causes gastroenteritis."
        }
      ],
      "biochemicalTests": "Gram-negative rod, motile, lactose –, H2S +, citrate +, urease –, lysine decarboxylase +."
    },
    "clinicalProfile": {
      "summary": "A foodborne or waterborne illness, often occurring in outbreaks. Clinical presentation ranges from self-limited gastroenteritis to severe systemic illness like enteric (typhoid) fever. Treatment is generally not recommended for mild-to-moderate gastroenteritis in immunocompetent patients but is indicated for severe illness, the immunocompromised, and others at risk of invasive disease.",
      "pathophysiologyPearls": [],
      "keySignsAndSymptoms": [
        "Diarrhea",
        "Fever",
        "Abdominal cramps",
        "Headache",
        "Rose spots (in Typhoid fever)"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Gastroenteritis",
          "description": "Inflammation of the stomach and intestines, typically resulting in vomiting and diarrhea."
        },
        {
          "syndromeName": "Enteric Fever (Typhoid Fever)",
          "description": "A systemic illness caused by Salmonella Typhi or Paratyphi, characterized by sustained fever, headache, and abdominal pain."
        },
        {
          "syndromeName": "Bacteremia",
          "description": "Presence of Salmonella in the bloodstream, can occur with or without focal infection."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Immunocompromised patients",
        "Young children",
        "The elderly"
      ],
      "transmissionVectors": [
        "Foodborne",
        "Waterborne"
      ],
      "prognosisNotes": [
        "Relapse can occur (1-6% with fluoroquinolones/Ceftriaxone, up to 20% with Chloramphenicol).",
        "Chronic carriage (excretion for >1 year) occurs in 1-6% of patients, especially those with cholelithiasis."
      ]
    },
    "resistanceProfile": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Empiric Therapy Warning",
          "details": "Ampicillin, TMP-SMX, and Chloramphenicol should not be used empirically due to high resistance rates. Treatment should be guided by the region where the isolate was acquired."
        },
        {
          "alertTitle": "Extensively Drug-Resistant (XDR) Strains",
          "details": "MDR and XDR isolates are emerging, especially in South Asia. S. Typhi is more frequently XDR than non-typhoidal Salmonella."
        }
      ]
    },
    "treatment": {
      "generalNotes": [
        "Longer duration of therapy (e.g., 14 days or more) is recommended for immunocompromised patients."
      ],
      "drugsToAvoid": [],
      "adjunctiveTherapies": [
        {
          "therapy": "Dexamethasone",
          "condition": "Severe Typhoid Fever",
          "details": "Consider concomitant Dexamethasone (3 mg/kg IV loading dose, then 1 mg/kg IV q6h for 48 hrs)."
        }
      ],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Severe illness, invasive disease",
            "patientPopulation": [
              "Adults"
            ],
            "isolateSource": "Blood, Stool"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "7-14 days",
                  "drugs": [
                    {
                      "drugName": "Ciprofloxacin",
                      "dose": "400 mg IV or 500 mg PO",
                      "route": "IV/PO",
                      "frequency": "bid",
                      "comments": "Not recommended if Salmonella Typhi (Typhoid fever) is suspected due to extensive XDR, especially from Asia."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "7-14 days",
                  "drugs": [
                    {
                      "drugName": "Levofloxacin",
                      "dose": "750 mg",
                      "route": "IV/PO",
                      "frequency": "once daily",
                      "comments": "Not recommended if Salmonella Typhi (Typhoid fever) is suspected due to extensive XDR, especially from Asia."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "7-14 days",
                  "drugs": [
                    {
                      "drugName": "Ceftriaxone",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "once daily",
                      "comments": "Preferred if there is a history of travel to Asia or other regions with high fluoroquinolone resistance."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Meropenem",
                      "dose": "1-2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "For severely ill patients or when XDR is suspected."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Sequential",
              "steps": [
                {
                  "step": 1,
                  "duration": "1 day",
                  "drugs": [
                    {
                      "drugName": "Azithromycin",
                      "dose": "1 gm",
                      "route": "IV/PO",
                      "frequency": "once",
                      "comments": ""
                    }
                  ]
                },
                {
                  "step": 2,
                  "duration": "4-6 days",
                  "drugs": [
                    {
                      "drugName": "Azithromycin",
                      "dose": "500 mg",
                      "route": "IV/PO",
                      "frequency": "once daily",
                      "comments": "Total duration 5-7 days."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "14 days",
                  "drugs": [
                    {
                      "drugName": "Chloramphenicol",
                      "dose": "2-3 gm/day",
                      "route": "IV/PO",
                      "frequency": "in 4 divided doses",
                      "comments": "Use if other agents are not available."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "7-14 days",
                  "drugs": [
                    {
                      "drugName": "Cefixime",
                      "dose": "20-30 mg/kg/day",
                      "route": "PO",
                      "frequency": "in two divided doses",
                      "comments": "Experience is mixed; may not perform as well as other agents."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "TMP-SMX",
                      "dose": "8-10 mg/kg of TMP component",
                      "route": "IV/PO",
                      "frequency": "in 2-3 divided doses",
                      "comments": "Use only if confirmed susceptible in vitro."
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "laboratoryProfile": {
      "testingIndications": [
        "CLSI has established breakpoints for Ciprofloxacin susceptibility. Specific testing methods are recommended to detect decreased ciprofloxacin susceptibility, as higher MICs correlate with resistance mechanisms."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    },
    "additionalInformation": {
      "diagnosticNotes": {
        "summary": "",
        "biosafetyWarning": "",
        "methods": []
      },
      "preventionAndScreening": [],
      "treatmentLifecycle": [],
      "antimicrobialStewardship": [
        "Antimicrobial therapy for uncomplicated gastroenteritis may prolong carriage."
      ],
      "drugSpecificPearls": [],
      "guidelineReferences": []
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "laboratoryProfile",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.342Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Salmonella sp."
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": [
        "Salmonella enterica serovars",
        "Salmonella Typhi",
        "Salmonella Paratyphi",
        "Salmonella Choleraesuis",
        "Salmonella Typhimurium"
      ]
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2023-11-14"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram-negative",
        "morphology": "Bacillus",
        "respiration": "Facultative anaerobe",
        "notes": []
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "A foodborne or waterborne illness, often occurring in outbreaks. Clinical presentation ranges from self-limited gastroenteritis to severe systemic illness like enteric (typhoid) fever. Treatment is generally not recommended for mild-to-moderate gastroenteritis in immunocompetent patients but is indicated for severe illness, the immunocompromised, and others at risk of invasive disease.",
      "pathophysiologyPearls": [],
      "keySignsAndSymptoms": [
        "Diarrhea",
        "Fever",
        "Abdominal cramps",
        "Headache",
        "Rose spots (in Typhoid fever)"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Gastroenteritis",
          "description": "Inflammation of the stomach and intestines, typically resulting in vomiting and diarrhea."
        },
        {
          "syndromeName": "Enteric Fever (Typhoid Fever)",
          "description": "A systemic illness caused by Salmonella Typhi or Paratyphi, characterized by sustained fever, headache, and abdominal pain."
        },
        {
          "syndromeName": "Bacteremia",
          "description": "Presence of Salmonella in the bloodstream, can occur with or without focal infection."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Immunocompromised patients",
        "Young children",
        "The elderly"
      ],
      "transmissionVectors": [
        "Foodborne",
        "Waterborne"
      ],
      "prognosisNotes": [
        "Relapse can occur (1-6% with fluoroquinolones/Ceftriaxone, up to 20% with Chloramphenicol).",
        "Chronic carriage (excretion for >1 year) occurs in 1-6% of patients, especially those with cholelithiasis."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Empiric Therapy Warning",
          "details": "Ampicillin, TMP-SMX, and Chloramphenicol should not be used empirically due to high resistance rates. Treatment should be guided by the region where the isolate was acquired."
        },
        {
          "alertTitle": "Extensively Drug-Resistant (XDR) Strains",
          "details": "MDR and XDR isolates are emerging, especially in South Asia. S. Typhi is more frequently XDR than non-typhoidal Salmonella."
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-0-0-0",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ciprofloxacin",
              "dose": "400 mg IV or 500 mg PO",
              "route": "IV/PO",
              "frequency": "bid",
              "duration": "7-14 days",
              "comments": "Not recommended if Salmonella Typhi (Typhoid fever) is suspected due to extensive XDR, especially from Asia.",
              "originalText": "Ciprofloxacin 400 mg IV or 500 mg PO IV/PO bid"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-0",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Levofloxacin",
              "dose": "750 mg",
              "route": "IV/PO",
              "frequency": "once daily",
              "duration": "7-14 days",
              "comments": "Not recommended if Salmonella Typhi (Typhoid fever) is suspected due to extensive XDR, especially from Asia.",
              "originalText": "Levofloxacin 750 mg IV/PO once daily"
            }
          ]
        },
        {
          "regimenId": "modern-0-2-0",
          "extractedFrom": "treatment.regimens[0].recommendations[2].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftriaxone",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "once daily",
              "duration": "7-14 days",
              "comments": "Preferred if there is a history of travel to Asia or other regions with high fluoroquinolone resistance.",
              "originalText": "Ceftriaxone 2 gm IV once daily"
            }
          ]
        },
        {
          "regimenId": "modern-0-3-0",
          "extractedFrom": "treatment.regimens[0].recommendations[3].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Meropenem",
              "dose": "1-2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "For severely ill patients or when XDR is suspected.",
              "originalText": "Meropenem 1-2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-4-0",
          "extractedFrom": "treatment.regimens[0].recommendations[4].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Azithromycin",
              "dose": "1 gm",
              "route": "IV/PO",
              "frequency": "once",
              "duration": "1 day",
              "comments": "",
              "originalText": "Azithromycin 1 gm IV/PO once"
            }
          ]
        },
        {
          "regimenId": "modern-0-4-1",
          "extractedFrom": "treatment.regimens[0].recommendations[4].steps[1]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Azithromycin",
              "dose": "500 mg",
              "route": "IV/PO",
              "frequency": "once daily",
              "duration": "4-6 days",
              "comments": "Total duration 5-7 days.",
              "originalText": "Azithromycin 500 mg IV/PO once daily"
            }
          ]
        },
        {
          "regimenId": "modern-0-5-0",
          "extractedFrom": "treatment.regimens[0].recommendations[5].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Chloramphenicol",
              "dose": "2-3 gm/day",
              "route": "IV/PO",
              "frequency": "in 4 divided doses",
              "duration": "14 days",
              "comments": "Use if other agents are not available.",
              "originalText": "Chloramphenicol 2-3 gm/day IV/PO in 4 divided doses"
            }
          ]
        },
        {
          "regimenId": "modern-0-6-0",
          "extractedFrom": "treatment.regimens[0].recommendations[6].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Cefixime",
              "dose": "20-30 mg/kg/day",
              "route": "PO",
              "frequency": "in two divided doses",
              "duration": "7-14 days",
              "comments": "Experience is mixed; may not perform as well as other agents.",
              "originalText": "Cefixime 20-30 mg/kg/day PO in two divided doses"
            }
          ]
        },
        {
          "regimenId": "modern-0-7-0",
          "extractedFrom": "treatment.regimens[0].recommendations[7].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Severe illness, invasive disease",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": "Blood, Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "TMP-SMX",
              "dose": "8-10 mg/kg of TMP component",
              "route": "IV/PO",
              "frequency": "in 2-3 divided doses",
              "duration": "",
              "comments": "Use only if confirmed susceptible in vitro.",
              "originalText": "TMP-SMX 8-10 mg/kg of TMP component IV/PO in 2-3 divided doses"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile"
    ],
    "value": {
      "testingIndications": [
        "CLSI has established breakpoints for Ciprofloxacin susceptibility. Specific testing methods are recommended to detect decreased ciprofloxacin susceptibility, as higher MICs correlate with resistance mechanisms."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}